Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 20 de 506
Filtrar
1.
FASEB J ; 33(3): 3198-3211, 2019 03.
Artículo en Inglés | MEDLINE | ID: mdl-30379590

RESUMEN

Growth factor receptor-binding protein 10 (GRB10) is a well-known adaptor protein and a recently identified substrate of the mammalian target of rapamycin (mTOR). Depletion of GRB10 increases insulin sensitivity and overexpression suppresses PI3K/Akt signaling. Because the major reason for the limited efficacy of PI3K/Akt-targeted therapies in prostate cancer (PCa) is loss of mTOR-regulated feedback suppression, it is therefore important to assess the functional importance and regulation of GRB10 under these conditions. On the basis of these background observations, we explored the status and functional impact of GRB10 in PCa and found maximum expression in phosphatase and tensin homolog (PTEN)-deficient PCa. In human PCa samples, GRB10 inversely correlated with PTEN and positively correlated with pAKT levels. Knockdown of GRB10 in nontumorigenic PTEN null mouse embryonic fibroblasts and tumorigenic PCa cell lines reduced Akt phosphorylation and selectively activated a panel of receptor tyrosine kinases. Similarly, overexpression of GRB10 in PTEN wild-type PCa cell lines accelerated tumorigenesis and induced Akt phosphorylation. In PTEN wild-type PCa, GRB10 overexpression promoted mediated PTEN interaction and degradation. PI3K (but not mTOR) inhibitors reduced GRB10 expression, suggesting primarily PI3K-driven regulation of GRB10. In summary, our results suggest that GRB10 acts as a major downstream effector of PI3K and has tumor-promoting effects in prostate cancer.-Khan, M. I., Al Johani, A., Hamid, A., Ateeq, B., Manzar, N., Adhami, V. M., Lall, R. K., Rath, S., Sechi, M., Siddiqui, I. A., Choudhry, H., Zamzami, M. A., Havighurst, T. C., Huang, W., Ntambi, J. M., Mukhtar, H. Proproliferatve function of adaptor protein GRB10 in prostate carcinoma.


Asunto(s)
Proteína Adaptadora GRB10/metabolismo , Neoplasias de la Próstata/metabolismo , Neoplasias de la Próstata/patología , Animales , Carcinógenos/antagonistas & inhibidores , Carcinógenos/metabolismo , Línea Celular Tumoral , Proliferación Celular/genética , Proliferación Celular/fisiología , Fibroblastos/citología , Fibroblastos/metabolismo , Proteína Adaptadora GRB10/antagonistas & inhibidores , Proteína Adaptadora GRB10/genética , Técnicas de Silenciamiento del Gen , Humanos , Masculino , Diana Mecanicista del Complejo 1 de la Rapamicina/metabolismo , Ratones , Modelos Biológicos , Fosfohidrolasa PTEN/deficiencia , Fosfohidrolasa PTEN/genética , Fosfohidrolasa PTEN/metabolismo , Fosfatidilinositol 3-Quinasas/metabolismo , Neoplasias de la Próstata/genética , ARN Mensajero , Transducción de Señal
2.
Prostate ; 79(14): 1611-1621, 2019 10.
Artículo en Inglés | MEDLINE | ID: mdl-31348843

RESUMEN

BACKGROUND: The transcription factor signal transducer and activator of transcription 3 (STAT3) is implicated in cancer drug resistance, metastasis, and immunosuppression and has been identified as a promising therapeutic target for new anticancer drugs. Myeloid-derived suppressor cells (MDSCs) play a major role in the suppression of antitumor immunity and STAT3 is involved in the accumulation, generation, and function of MDSCs. Thus, targeting STAT3 holds the potential of reversing immunosuppression in cancer. This study aims to investigate the effect of the small molecule STAT3 inhibitor galiellalactone on prostate cancer cell- induced generation of MDSCs from monocytes and the effect on immunosuppressive factors and inflammatory cytokines. METHODS: Primary human monocytes were cocultured with prostate cancer cells (DU145, PC3, and LNCaP-IL6) or with conditioned medium (CM) from prostate cancer cells in the presence or absence of the STAT3 inhibitor galiellalactone. Monocytes were analyzed by flow cytometry for an MDSC-like phenotype (CD14+ HLA-DR-/lo ). The secretion and gene expression of immunosuppressive factors and inflammatory cytokines from prostate cancer cells and monocytes were investigated. RESULTS: Galiellalactone blocked the prostate cancer cell-induced generation of MDSC-like monocytes with an immunosuppressive phenotype ex vivo. Monocytes cultured with CM from prostate cancer cells showed increased expression of phosphorylated STAT3. Prostate cancer cells increased the expression of interleukin1ß (IL1ß), IL10, and IL6 in monocytes which was inhibited by galiellalactone. In addition, galiellalactone decreased indoleamine 2,3-dioxygenase gene expression in monocytes. Galiellalactone reduced the levels of IL8 and granulocyte macrophage-colony stimulating factor in prostate cancer cells per se. CONCLUSION: The STAT3 inhibitor galiellalactone may prevent the prostate cancer cell-induced generation of MDSCs and reverse the immunosuppressive mechanisms caused by the interplay between prostate cancer cells and MDSCs. This is a potential new immunotherapeutic approach for the treatment of prostate cancer.


Asunto(s)
Carcinógenos/antagonistas & inhibidores , Inmunosupresores/antagonistas & inhibidores , Lactonas/farmacología , Células Supresoras de Origen Mieloide/efectos de los fármacos , Neoplasias de la Próstata/patología , Factor de Transcripción STAT3/antagonistas & inhibidores , Carcinogénesis/efectos de los fármacos , Carcinógenos/metabolismo , Técnicas de Cocultivo , Citocinas/antagonistas & inhibidores , Citocinas/metabolismo , Humanos , Inmunosupresores/metabolismo , Masculino , Monocitos/efectos de los fármacos , Monocitos/metabolismo , Monocitos/patología , Células Supresoras de Origen Mieloide/metabolismo , Células Supresoras de Origen Mieloide/patología , Neoplasias de la Próstata/metabolismo , Células Tumorales Cultivadas
3.
J Appl Toxicol ; 37(4): 417-425, 2017 04.
Artículo en Inglés | MEDLINE | ID: mdl-27581495

RESUMEN

A body of epidemiological evidence implicates exposure to endocrine disrupting chemicals (EDCs) with increased susceptibility to breast cancer. To evaluate the physiological effects of a suspected EDC in vivo, we exposed MCF-7 breast cancer cells and a patient-derived xenograft (PDX, estrogen receptor positive) to physiological levels of methylparaben (mePB), which is commonly used in personal care products as a preservative. mePB pellets (4.4 µg per day) led to increased tumor size of MCF-7 xenografts and ER+ PDX tumors. mePB has been thought to be a xenoestrogen; however, in vitro exposure of 10 nM mePB failed to increase MCF-7 cell proliferation or induction of canonical estrogen-responsive genes (pS2 and progesterone receptor), in contrast to 17ß-estradiol (E2) treatment. MCF-7 and PDX-derived mammospheres exhibited increased size and up-regulation of canonical stem cell markers ALDH1, NANOG, OCT4 and SOX2 when exposed to mePB; these effects were not observed for MDA-MB-231 (ER- ) mammospheres. As tumor-initiating cells (TICs) are also believed to be responsible for chemoresistance, mammospheres were treated with either tamoxifen or the pure anti-estrogen fulvestrant in the presence of mePB. Blocking the estrogenic response was not sufficient to block NANOG expression in mammospheres, pointing to a non-classic estrogen response or an ER-independent mechanism of mePB promotion of mammosphere activity. Overall, these results suggest that mePB increases breast cancer tumor proliferation through enhanced TIC activity, in part via regulation of NANOG, and that mePB may play a direct role in chemoresistance by modulating stem cell activity. Copyright © 2016 John Wiley & Sons, Ltd.


Asunto(s)
Neoplasias de la Mama/inducido químicamente , Neoplasias de la Mama/genética , Carcinógenos/toxicidad , Disruptores Endocrinos/toxicidad , Células Madre Neoplásicas/efectos de los fármacos , Parabenos/toxicidad , Receptores de Estrógenos/genética , Animales , Carcinógenos/antagonistas & inhibidores , Proliferación Celular/efectos de los fármacos , Estradiol/farmacología , Antagonistas de Estrógenos/farmacología , Femenino , Humanos , Células MCF-7 , Ratones , Ratones Desnudos , Proteínas de Neoplasias/genética , Ovariectomía , Ensayos Antitumor por Modelo de Xenoinjerto
4.
J Appl Toxicol ; 36(6): 777-89, 2016 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-26204821

RESUMEN

Triclosan (TCS) is an antimicrobial used widely in hospitals and personal care products, at ~10 mm. Human skin efficiently absorbs TCS. Mast cells are ubiquitous key players both in physiological processes and in disease, including asthma, cancer and autism. We previously showed that non-cytotoxic levels of TCS inhibit degranulation, the release of histamine and other mediators, from rat basophilic leukemia mast cells (RBL-2H3), and in this study, we replicate this finding in human mast cells (HMC-1.2). Our investigation into the molecular mechanisms underlying this effect led to the discovery that TCS disrupts adenosine triphosphate (ATP) production in RBL-2H3 cells in glucose-free, galactose-containing media (95% confidence interval EC50 = 7.5-9.7 µm), without causing cytotoxicity. Using these same glucose-free conditions, 15 µm TCS dampens RBL-2H3 degranulation by 40%. The same ATP disruption was found with human HMC-1.2 cells (EC50 4.2-13.7 µm), NIH-3 T3 mouse fibroblasts (EC50 4.8-7.4 µm) and primary human keratinocytes (EC50 3.0-4.1 µm) all with no cytotoxicity. TCS increases oxygen consumption rate in RBL-2H3 cells. Known mitochondrial uncouplers (e.g., carbonyl cyanide 3-chlorophenylhydrazone) previously were found to inhibit mast cell function. TCS-methyl, which has a methyl group in place of the TCS ionizable proton, affects neither degranulation nor ATP production at non-cytotoxic doses. Thus, the effects of TCS on mast cell function are due to its proton ionophore structure. In addition, 5 µm TCS inhibits thapsigargin-stimulated degranulation of RBL-2H3 cells: further evidence that TCS disrupts mast cell signaling. Our data indicate that TCS is a mitochondrial uncoupler, and TCS may affect numerous cell types and functions via this mechanism. Copyright © 2015 John Wiley & Sons, Ltd.


Asunto(s)
Antiinfecciosos Locales/farmacología , Queratinocitos/efectos de los fármacos , Mastocitos/efectos de los fármacos , Mitocondrias/efectos de los fármacos , Fosforilación Oxidativa/efectos de los fármacos , Triclosán/farmacología , Desacopladores/farmacología , Animales , Antiinfecciosos Locales/efectos adversos , Anticarcinógenos/efectos adversos , Anticarcinógenos/farmacología , Carcinógenos/antagonistas & inhibidores , Carcinógenos/toxicidad , Degranulación de la Célula/efectos de los fármacos , Línea Celular , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Humanos , Queratinocitos/metabolismo , Cinética , Mastocitos/inmunología , Mastocitos/metabolismo , Ratones , Mitocondrias/metabolismo , Células 3T3 NIH , Ratas , Tapsigargina/antagonistas & inhibidores , Tapsigargina/toxicidad , Triclosán/efectos adversos , Triclosán/análogos & derivados , Desacopladores/efectos adversos
5.
Environ Toxicol ; 31(7): 782-98, 2016 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-26990576

RESUMEN

In the absence of an effective therapy against Hepatocellular Carcinoma (HCC), chemoprevention remains an important strategy to circumvent morbidity and mortality. Here, we examined chemopreventive potential of Acteoside (ACT), a plant derived phenylethanoid glycoside against an environmental and dietary carcinogen, diethylnitrosamine (DEN)-induced rat hepatocarcinogenesis. ACT treatment (0.1 and 0.3% supplemented with diet) started 2 weeks before DEN challenge and continued for 18 weeks thereafter, showed a remarkable chemopreventive activity. ACT treatment resulted in reduced HCC nodules. Histopathology showed progressive tissue damage, necrosis (5 weeks), hepatocytic injury (10 weeks), anisonucleosis with presence of prominent nucleoli, sinusidal dilations, and lymphomono nuclear inflammation (18 weeks). Biochemical analysis showed hepatocytic injury (raised ALT, p < 0.001), inflammation [IL-6, IFN-γ (p < 0.05), and TNF-α (p < 0.001)], apoptosis [elevated Caspase-3 (p < 0.001)]. ACT at 0.1 and 0.3% ameliorated DEN-induced pre-hepatocarcinogenic manifestations. Mechanistic studies of ACT chemoprevention was elucidated using Hep3B cells with an aim to develop an in vitro DEN-induced toxicity model. Hep3B was found to be a reliable and more sensitive towards DEN toxicity compared to HepG2 and HuH7 cells. ACT prevented DEN-induced cytotoxicity (p < 0.001), DNA damage, and genotoxicity (micronuclei test, DNA ladder test, Hoechst staining, cell cycle analysis). ACT significantly (p < 0.001) scavenged DEN-induced reactive oxygen species (ROS) levels and prevented mitochondrial membrane potential (MMP) loss. Immunoblotting showed ACT treatment reversed DEN-induced NF-κB, Bax, Cytochrome C, Bcl-2, and Stat-3 levels. We conclude that chemoprotective effect of ACT is mediated by STAT-3 dependent regulation of oxidative stress and apoptosis and ACT has potential to be developed as a chemopreventive agent. © 2015 Wiley Periodicals, Inc. Environ Toxicol 31: 782-798, 2016.


Asunto(s)
Anticarcinógenos/farmacología , Antineoplásicos Fitogénicos/farmacología , Apoptosis/efectos de los fármacos , Glucósidos/farmacología , Estrés Oxidativo/efectos de los fármacos , Fenoles/farmacología , Factor de Transcripción STAT3/efectos de los fármacos , Animales , Carcinógenos/antagonistas & inhibidores , Carcinógenos/toxicidad , Línea Celular Tumoral , Citocinas/metabolismo , Dietilnitrosamina/antagonistas & inhibidores , Dietilnitrosamina/toxicidad , Hepatocitos/efectos de los fármacos , Hepatocitos/patología , Neoplasias Hepáticas Experimentales/inducido químicamente , Neoplasias Hepáticas Experimentales/patología , Neoplasias Hepáticas Experimentales/prevención & control , Masculino , Ratas , Ratas Wistar
6.
J Sci Food Agric ; 96(2): 548-54, 2016 Jan 30.
Artículo en Inglés | MEDLINE | ID: mdl-25656956

RESUMEN

BACKGROUND: Acrylamide (AA) is a potential carcinogen which widely exists in heat-processed foods. The addition of glycine (Gly) has been shown to reduce the formation of AA. The objective of this work was to investigate the kinetics of the inhibition of AA by Gly in both asparagine (Asn)/glucose (Glc) and Asn/Glc/Gly potato model systems during heating at 160 °C, 180 °C, and 200 °C. RESULTS: The simplified two consecutive first-order kinetic model fitted well to the changes of AA in both systems. No significant difference in rate constant (kF) and apparent activation energy (EaF) was observed for AA formation between the two systems (P > 0.05). Whereas EaE and only kE at 200 °C for AA elimination in the Asn/Glc/Gly system was significantly higher than Asn/Glc system (P < 0.05). The elimination reaction between Gly and AA was confirmed by the identification of their major reaction product 2-((3-amino-3-oxopropyl)amino)acetic acid in the Asn/Glc/(15) N-Gly system. CONCLUSION: The reduction of AA by Gly is predominantly attributed to the elimination reaction between Gly and AA.


Asunto(s)
Acrilamida/antagonistas & inhibidores , Glicina/farmacología , Solanum tuberosum/química , Acrilamida/análisis , Acrilamida/química , Asparagina/análisis , Asparagina/química , Carcinógenos/antagonistas & inhibidores , Carcinógenos/química , Cromatografía Líquida de Alta Presión , Glucosa/análisis , Glucosa/química , Glicina/análisis , Glicina/química , Calor , Cinética , Espectrometría de Masas en Tándem , Termodinámica
7.
Nutr Cancer ; 67(1): 167-76, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25437343

RESUMEN

DNA methyltransferase 1 (DNMT1), a key enzyme mediating DNA methylation, is known to be elevated in various cancers, including the mouse lung tumors induced by the tobacco-specific carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). However, it is not known whether DNMT1 expression is induced right after NNK treatment and how DNMT1 expression varies throughout lung tumorigenesis. In the present study, we found that administration of NNK to A/J mice caused elevation of DNMT1 in bronchial epithelial cells at Days 1, 3, and 14 after NNK treatment. DNMT1 elevation at Day 1 was accompanied by an increase in phospho-histone H2AX (γ-H2AX) and phospho-AKT (p-AKT). At Weeks 5 to 20, NNK-induced DNMT1 in lung tissues was in lower levels than the early stages, but was highly elevated in lung tumors at Week 20. In addition, the early induction of p-AKT and γ-H2AX as well as cleaved caspase-3 in NNK-treated lung tissues was not detected at Weeks 5 to 20 but was elevated in lung tumors. In concordance with DNMT1 elevation, promoter hypermethylation of tumor suppressor genes Cdh13, Prdm2, and Runx3 was observed in lung tissues at Day 3 and in lung tumors. Treatment by EGCG attenuated DNMT1, p-AKT, and γ-H2AX inductions at Days 1 and 3 and inhibited lung tumorigenesis.


Asunto(s)
Anticarcinógenos/uso terapéutico , Catequina/análogos & derivados , ADN (Citosina-5-)-Metiltransferasas/antagonistas & inhibidores , Suplementos Dietéticos , Regulación Neoplásica de la Expresión Génica , Neoplasias Pulmonares/prevención & control , Pulmón/metabolismo , Animales , Antineoplásicos Fitogénicos/uso terapéutico , Bronquios/efectos de los fármacos , Bronquios/metabolismo , Bronquios/patología , Carcinogénesis/inducido químicamente , Carcinogénesis/metabolismo , Carcinogénesis/patología , Carcinógenos/antagonistas & inhibidores , Carcinógenos/toxicidad , Catequina/uso terapéutico , ADN (Citosina-5-)-Metiltransferasa 1 , ADN (Citosina-5-)-Metiltransferasas/química , ADN (Citosina-5-)-Metiltransferasas/genética , ADN (Citosina-5-)-Metiltransferasas/metabolismo , Metilación de ADN/efectos de los fármacos , Femenino , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Pulmón/efectos de los fármacos , Pulmón/patología , Neoplasias Pulmonares/inducido químicamente , Neoplasias Pulmonares/dietoterapia , Neoplasias Pulmonares/metabolismo , Ratones Endogámicos A , Proteínas de Neoplasias/agonistas , Proteínas de Neoplasias/antagonistas & inhibidores , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/metabolismo , Nitrosaminas/antagonistas & inhibidores , Nitrosaminas/toxicidad , Regiones Promotoras Genéticas/efectos de los fármacos , Mucosa Respiratoria/efectos de los fármacos , Mucosa Respiratoria/metabolismo , Mucosa Respiratoria/patología
8.
Toxicol Ind Health ; 31(12): 1195-201, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23723263

RESUMEN

BACKGROUND: Nitrobenzene is a carcinogen, which induces-among others-thyroid tumors. Melatonin is an effective antioxidant, whereas some antioxidative effects of propylthiouracil (PTU; an antithyroid medication used for the treatment of thyrotoxicosis) were also found. The aim of the study was to compare protective effects of melatonin and PTU against lipid peroxidation in homogenates of porcine thyroids, incubated in the presence of nitrobenzene. METHODS: Homogenates of porcine thyroids were incubated for 30 min in the presence of nitrobenzene (0.001, 0.01, 0.1, 0.25, 0.5, 1.0, 2.5, 5.0, 7.5, and 10.0 mM). The level of lipid peroxidation products (malondialdehyde + 4-hydroxyalkenals) was measured spectrophotometrically. Nitrobenzene (7.5 and 10.0 mM) increased lipid peroxidation in the homogenates of porcine thyroids. Subsequently, homogenates of porcine thyroids were incubated for 30 min in the presence of nitrobenzene (7.5 mM) plus one of the antioxidants: melatonin (0.000001, 0.00001, 0.0001, 0.001, 0.01, 0.1, 0.25, 0.5, 1.0, 2.5, 5.0, and 7.5 mM) or PTU (0.01, 0.1, 0.25, 0.5, 1.0, 2.5, 5.0, and 7.5 mM). RESULTS: Lipid peroxidation caused by nitrobenzene was effectively prevented by melatonin, with the lowest effective concentration of 0.0001 mM, being only two orders of magnitude higher than physiological blood concentration in humans. At the same time, PTU revealed protective effects only in the highest used concentration (7.5 mM), which is practically never reached during pharmacological treatment in patients with thyrotoxicosis. CONCLUSIONS: Melatonin can serve as an effective agent in protection against nitrobenzene-induced lipid peroxidation in porcine thyroid.


Asunto(s)
Anticarcinógenos/farmacología , Carcinógenos/antagonistas & inhibidores , Peroxidación de Lípido/efectos de los fármacos , Melatonina/farmacología , Nitrobencenos/antagonistas & inhibidores , Propiltiouracilo/farmacología , Glándula Tiroides/efectos de los fármacos , Mataderos , Animales , Antioxidantes/farmacología , Antitiroideos/farmacología , Biomarcadores/química , Biomarcadores/metabolismo , Carcinógenos/toxicidad , Sistema Libre de Células/efectos de los fármacos , Sistema Libre de Células/metabolismo , Compuestos Cromogénicos/química , Indoles/química , Masculino , Malondialdehído/química , Malondialdehído/metabolismo , Nitrobencenos/toxicidad , Concentración Osmolar , Sus scrofa , Glándula Tiroides/metabolismo
9.
Nutr Cancer ; 66(2): 308-14, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24380573

RESUMEN

Epidermal growth factor receptor (EGFR) plays an important role in epithelial carcinogenesis and appears to be involved in STATs activation. In this study we investigated the possible interference of naturally occurring phenolic acids with EGFR, activator protein-1 (AP-1), and signal transducers and activators of transcription (STATs) pathways activated by topical application of tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) in Balb/c mice epidermis. Pretreatment with tannic or chlorogenic acid resulted in a significant decrease in the phosphorylation of EGFR Y-1068 and Y-1173 tyrosine residues, which was accompanied by reduced activation of AP-1. Tannic acid decreased also the c-Jun AP-1 subunit level and binding to TPA response element (TRE) (3- and 2-fold in comparison with TPA-treated group respectively). Simultaneous reduction of JNK activity might be responsible for reduced activation of AP-1. In contrast to these more complex phenolics, protocatechuic acid increased the activity of JNK and was also the most efficient inhibitor of STATs activation. These results indicate that naturally occurring phenolic acids, by decreasing EGFR, AP-1, and STATs activation, may modulate other elements both upstream and downstream in these pathways and thus inhibit the tumor development. Although more complex phenolics affect mainly the EGFR/AP-1 pathway, STATs seem to be the most important targets for simple compounds, such as protocatechuic acid.


Asunto(s)
Epidermis/efectos de los fármacos , Receptores ErbB/metabolismo , Hidroxibenzoatos/farmacología , Acetato de Tetradecanoilforbol/toxicidad , Factor de Transcripción AP-1/metabolismo , Animales , Carcinógenos/administración & dosificación , Carcinógenos/antagonistas & inhibidores , Carcinógenos/toxicidad , Ácido Clorogénico/farmacología , Epidermis/metabolismo , Receptores ErbB/genética , Femenino , Ratones , Ratones Endogámicos BALB C , Fosforilación , Factor de Transcripción STAT3/genética , Factor de Transcripción STAT3/metabolismo , Factor de Transcripción STAT5/genética , Factor de Transcripción STAT5/metabolismo , Transducción de Señal , Taninos/farmacología , Acetato de Tetradecanoilforbol/administración & dosificación , Acetato de Tetradecanoilforbol/antagonistas & inhibidores , Factor de Transcripción AP-1/genética
10.
Toxicol Mech Methods ; 24(8): 593-602, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25156538

RESUMEN

The possible molecular mechanisms of Nano-selenium (nano-se) in attenuating hepatocellular carcinoma (HCC) was investigated in this study. To achieve this target, the apoptotic/necrotic rate in hepatic cells was investigated morphologically by double staining with acridine orange/ethidium bromide to address the type of cell death induced by nano-Se in HCC-bearing rats. To predict the oxidative stress and DNA damage, the generation of 8-hydroxy-2-deoxyguanosine (8-OHdG) and 2-deoxyguanosine (2-dG) was examined. Moreover, the expression of some HCC-related genes was investigated such as aldo-keto reductase 1B10 (Akr1b10), ING3 and Foxp1 genes. As well as the histopathological study of liver tissue sections was performed. The results obtained from this study revealed that (HCC+Nano Se) group shows the highest number of damaged cancerous cells. Furthermore, the necrotic/apoptotic rate was significantly higher in (nano-Se+HCC), (HCC+Doxo) and (HCC+Doxo+nano-se) compared to that in the untreated HCC group. Treatment of HCC group with nano-se decreased the ratio of 8-OHdG/2-dG generation significantly with respect to the untreated HCC group. The opposite was observed regarding the gene expression of AKr1b10 and ING3. The treatment of HCC group with nano-se elicited significant increase in the expression of Akr1b10 and ING3 genes compared with untreated HCC group. On the other hand, the expression of Foxp1 gene was significantly decreased in HCC group treated with nano-se in comparison with the untreated HCC group. The histopathological study provided a supportive evidence for the molecular genetics study. Our data shed light on the molecular mechanisms of nano-se in attenuating HCC in the experimental model.


Asunto(s)
Anticarcinógenos/uso terapéutico , Carcinógenos/antagonistas & inhibidores , Carcinoma Hepatocelular/prevención & control , Neoplasias Hepáticas/prevención & control , Hígado/efectos de los fármacos , Nanopartículas/uso terapéutico , Selenio/uso terapéutico , Aldehído Reductasa/química , Aldehído Reductasa/genética , Aldehído Reductasa/metabolismo , Alquilantes/química , Alquilantes/toxicidad , Animales , Apoptosis/efectos de los fármacos , Biomarcadores/metabolismo , Carcinógenos/toxicidad , Carcinoma Hepatocelular/inducido químicamente , Carcinoma Hepatocelular/metabolismo , Carcinoma Hepatocelular/patología , Daño del ADN/efectos de los fármacos , Dietilnitrosamina/antagonistas & inhibidores , Dietilnitrosamina/toxicidad , Factores de Transcripción Forkhead/antagonistas & inhibidores , Factores de Transcripción Forkhead/genética , Factores de Transcripción Forkhead/metabolismo , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Hígado/metabolismo , Hígado/patología , Neoplasias Hepáticas/inducido químicamente , Neoplasias Hepáticas/metabolismo , Neoplasias Hepáticas/patología , Masculino , Necrosis , Estrés Oxidativo/efectos de los fármacos , Ratas Sprague-Dawley , Proteínas Represoras/antagonistas & inhibidores , Proteínas Represoras/genética , Proteínas Represoras/metabolismo , Organismos Libres de Patógenos Específicos , Proteínas Supresoras de Tumor/química , Proteínas Supresoras de Tumor/genética , Proteínas Supresoras de Tumor/metabolismo
11.
J Proteome Res ; 11(2): 1302-16, 2012 Feb 03.
Artículo en Inglés | MEDLINE | ID: mdl-22115128

RESUMEN

Oral cancer typically develops from hyperplasia through dysplasia to carcinoma with a multistep process of carcinogenesis involving genetic alterations resulting in aberrant cellular appearance, deregulated cell growth, and carcinoma. The metabolic transformation during the process of oral carcinogenesis and its implications for cancer therapy have not been extensively investigated. Here, we report a metabonomic study on a classical model of 7,12-dimethylbenz(a)anthracene (DMBA)-induced oral carcinogenesis in hamsters to delineate characteristic metabolic transformation during the carcinogenesis using gas chromatography time-of-flight mass spectrometry (GC-TOF MS). Salvianolic acid B (Sal-B), isolated from Salvia miltiorrhiza Bge, and Breviscapine, a flavonoid isolated from Herba Erigerontis, were used to treat the hamsters exposed to DMBA to investigate the molecular mechanism of the inhibitory effect of the two agents on oral carcinogenesis. The dynamic changes of serum metabolic profiles indicated that both Sal-B and Breviscapine were able to attenuate DMBA-induced metabolic perturbation, which is consistent with the histopathological findings that Sal-B and Breviscapine significantly decreased the squamous cell carcinoma (SCC) incidence in the two treatment groups. Significant alterations of key metabolic pathways, including elevated glutaminolysis and glycolysis, and decreased cholesterol and myo-inositol metabolism, were observed in the DMBA-induced model group, which were attenuated or normalized by Sal-B or Breviscapine treatment. Elevated inflammation and tumor angiogenesis at gene and metabolite expression levels were also observed in DMBA-induced oral dysplasia and SCC but were attenuated or normalized by Sal-B and Breviscapine along with significantly decreased incidences of SCC formation.


Asunto(s)
9,10-Dimetil-1,2-benzantraceno/antagonistas & inhibidores , Benzofuranos/farmacología , Carcinógenos/antagonistas & inhibidores , Flavonoides/farmacología , Neoplasias de la Boca/metabolismo , Neoplasias de la Boca/prevención & control , 9,10-Dimetil-1,2-benzantraceno/farmacocinética , 9,10-Dimetil-1,2-benzantraceno/toxicidad , Animales , Carcinógenos/farmacocinética , Carcinógenos/toxicidad , Cricetinae , Interacciones Farmacológicas , Cromatografía de Gases y Espectrometría de Masas , Histocitoquímica , Masculino , Mesocricetus , Redes y Vías Metabólicas/efectos de los fármacos , Metaboloma/efectos de los fármacos , Metabolómica , Neoplasias de la Boca/irrigación sanguínea , Neoplasias de la Boca/inducido químicamente , Neovascularización Patológica/tratamiento farmacológico , Neovascularización Patológica/metabolismo
12.
Br J Nutr ; 108(6): 984-97, 2012 Sep 28.
Artículo en Inglés | MEDLINE | ID: mdl-22182368

RESUMEN

The role of dietary factors in inhibiting or delaying the development of non-melanoma skin cancer (NMSC) has been investigated for many years. Cardamom, which is a dietary phytoproduct, has been commonly used in cuisines for flavour and has numerous health benefits, such as improving digestion and stimulating metabolism and having antitumorigenic effects. We have investigated the efficacy of dietary cardamom against 7,12-dimethylbenz[a]anthracene (DMBA)-induced skin papillomatogenesis in Swiss albino mice that closely resembles human NMSC. Mice were grouped into normal wild type (untreated), vehicle-treated (acetone), carcinogen-treated (DMBA), and DMBA and cardamom-treated (DMBA+CARD) to delineate the role of cardamom against DMBA-induced papillomatogenesis. Oral administration of cardamom to DMBA-treated mice up-regulated the phase II detoxification enzymes, such as glutathione-S-transferase and glutathione peroxidase, probably via activation of nuclear factor erythroid-2-related factor 2 transcription factor in 'DMBA+CARD' mice. Furthermore, reduced glutathione, glutathione reductase, superoxide dismutase and catalase were also up-regulated by cardamom in the same 'DMBA+CARD' group of mice compared with DMBA-treated mice. Cardamom ingestion in DMBA-treated mice blocked NF-κB activation and down-regulated cyclo-oxygenase-2 expression. As a consequence, both the size and the number of skin papillomas generated on the skin due to the DMBA treatment were reduced in the 'DMBA+CARD' group. Thus, the results from the present study suggest that cardamom has a potential to become a pivotal chemopreventive agent to prevent papillomagenesis on the skin.


Asunto(s)
Antioxidantes/uso terapéutico , Elettaria/química , Factor 2 Relacionado con NF-E2/metabolismo , FN-kappa B/metabolismo , Transducción de Señal , Neoplasias Cutáneas/prevención & control , Especias , 9,10-Dimetil-1,2-benzantraceno/antagonistas & inhibidores , 9,10-Dimetil-1,2-benzantraceno/toxicidad , Animales , Anticarcinógenos/uso terapéutico , Carcinógenos/antagonistas & inhibidores , Carcinógenos/toxicidad , Ciclooxigenasa 2/química , Ciclooxigenasa 2/metabolismo , Femenino , Fase II de la Desintoxicación Metabólica , Ratones , FN-kappa B/antagonistas & inhibidores , Proteínas de Neoplasias/metabolismo , Papiloma/inducido químicamente , Papiloma/metabolismo , Papiloma/patología , Papiloma/prevención & control , Semillas/química , Piel/efectos de los fármacos , Piel/metabolismo , Piel/patología , Neoplasias Cutáneas/inducido químicamente , Neoplasias Cutáneas/metabolismo , Neoplasias Cutáneas/patología , Carga Tumoral
13.
Nat Commun ; 13(1): 136, 2022 01 10.
Artículo en Inglés | MEDLINE | ID: mdl-35013263

RESUMEN

Emerging research supports that triclosan (TCS), an antimicrobial agent found in thousands of consumer products, exacerbates colitis and colitis-associated colorectal tumorigenesis in animal models. While the intestinal toxicities of TCS require the presence of gut microbiota, the molecular mechanisms involved have not been defined. Here we show that intestinal commensal microbes mediate metabolic activation of TCS in the colon and drive its gut toxicology. Using a range of in vitro, ex vivo, and in vivo approaches, we identify specific microbial ß-glucuronidase (GUS) enzymes involved and pinpoint molecular motifs required to metabolically activate TCS in the gut. Finally, we show that targeted inhibition of bacterial GUS enzymes abolishes the colitis-promoting effects of TCS, supporting an essential role of specific microbial proteins in TCS toxicity. Together, our results define a mechanism by which intestinal microbes contribute to the metabolic activation and gut toxicity of TCS, and highlight the importance of considering the contributions of the gut microbiota in evaluating the toxic potential of environmental chemicals.


Asunto(s)
Proteínas Bacterianas/antagonistas & inhibidores , Carcinógenos/antagonistas & inhibidores , Colitis/prevención & control , Neoplasias Colorrectales/prevención & control , Glucuronidasa/antagonistas & inhibidores , Inhibidores de Glicósido Hidrolasas/farmacología , Triclosán/antagonistas & inhibidores , Animales , Antiinfecciosos Locales/química , Antiinfecciosos Locales/metabolismo , Antiinfecciosos Locales/toxicidad , Anticarcinógenos/química , Anticarcinógenos/farmacología , Proteínas Bacterianas/química , Proteínas Bacterianas/genética , Proteínas Bacterianas/metabolismo , Sitios de Unión , Biotransformación , Carcinogénesis/efectos de los fármacos , Carcinogénesis/metabolismo , Carcinógenos/química , Carcinógenos/metabolismo , Carcinógenos/toxicidad , Colitis/inducido químicamente , Colitis/enzimología , Colitis/microbiología , Colon/efectos de los fármacos , Colon/microbiología , Colon/patología , Neoplasias Colorrectales/inducido químicamente , Neoplasias Colorrectales/enzimología , Neoplasias Colorrectales/microbiología , Microbioma Gastrointestinal/efectos de los fármacos , Expresión Génica , Glucuronidasa/química , Glucuronidasa/genética , Glucuronidasa/metabolismo , Inhibidores de Glicósido Hidrolasas/química , Humanos , Ratones , Ratones Endogámicos C57BL , Modelos Moleculares , Unión Proteica , Conformación Proteica en Hélice alfa , Conformación Proteica en Lámina beta , Dominios y Motivos de Interacción de Proteínas , Proteínas Recombinantes/química , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Triclosán/química , Triclosán/metabolismo , Triclosán/toxicidad
14.
Carcinogenesis ; 32(6): 913-20, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21459756

RESUMEN

The short chain fatty acid (SCFA) butyrate, a product of fermentation of dietary fiber in the human colon, is found to exert multiple regulatory processes in colon carcinogenesis. The aim of this study was to find out whether butyrate affects the tumor-promoting genes osteopontin (OPN) and cyclooxygenase (COX)-2, their respective proteins and/or their functional activity in matched normal, adenoma and tumor colon tissues obtained from 20 individuals at colon cancer surgery. Quantitative real-time polymerase chain reaction experiments showed increased levels of OPN and COX-2 messenger RNA in tumor tissues when compared with the adjacent normal samples (P < 0.001). The addition of butyrate reduced OPN and COX-2 mRNA expression in all tissue types compared with the related medium controls (tumor: P < 0.05). In tumor samples, a downregulation of up to median 35% (COX-2) and 50% (OPN) was observed, respectively. Thereby, tumors with lower levels of OPN basal expression were more sensitive to inhibition and vice versa for COX-2 in normal tissue. At the protein and enzyme level, which were determined by using western blot and enzyme immunometric assays, the impact of the SCFA was not clearly visible anymore. The active proteins of OPN and COX-2 (determined by prostaglandin E(2)) were found to correlate with their respective mRNA expression only in 50-63% of analyzed donors. For the first time, our data reveal new insights into the chemoprotective potential of butyrate by showing the suppression of OPN and COX-2 mRNA in primary human colon tissue with the strongest effects observed in tumors.


Asunto(s)
Adenoma/genética , Butiratos/farmacología , Neoplasias Colorrectales/genética , Ciclooxigenasa 2/genética , Osteopontina/genética , ARN Mensajero/antagonistas & inhibidores , Adenoma/tratamiento farmacológico , Adenoma/metabolismo , Anciano , Western Blotting , Carcinógenos/antagonistas & inhibidores , Neoplasias Colorrectales/tratamiento farmacológico , Neoplasias Colorrectales/metabolismo , Ciclooxigenasa 2/metabolismo , Femenino , Humanos , Masculino , Osteopontina/metabolismo , ARN Mensajero/genética , ARN Mensajero/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
15.
Biosci Biotechnol Biochem ; 75(6): 1167-73, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21670518

RESUMEN

Aplog-1 is a unique analog of tumor-promoting aplysiatoxin that inhibits tumor-promotion by phorbol diesters and proliferation of tumor cells. While the structural features relevant to the biological activities of Aplog-1 remain to be identified, recent studies by us have suggested that local hydrophobicity around the spiroketal moiety of Aplog-1 is a crucial determinant of its anti-proliferative activity. This hypothesis led us to design 12,12-dimethyl-Aplog-1 (3), in which a hydrophobic geminal dimethyl group is installed proximal to the spiroketal moiety to improve biological potency. As expected, 3 was more effective than Aplog-1 in inhibiting cancer cell growth and binding to protein kinase Cδ, a putative receptor responsible for the biological response of Aplog-1. Moreover, an induction test on Epstein-Barr virus early antigen demonstrated 3 to be a better anti-tumor promoter than Aplog-1. These results indicate that 3 is a superior derivative of Aplog-1, and thus a more promising lead for anti-cancer drugs.


Asunto(s)
Anticarcinógenos/farmacología , Antígenos Virales/análisis , Linfocitos B/virología , Infecciones por Virus de Epstein-Barr/prevención & control , Furanos/farmacología , Herpesvirus Humano 4/efectos de los fármacos , Toxinas de Lyngbya/efectos adversos , Neoplasias/prevención & control , Compuestos de Espiro/farmacología , Anticarcinógenos/síntesis química , Antígenos Virales/biosíntesis , Linfocitos B/patología , Carcinógenos/antagonistas & inhibidores , Carcinógenos/farmacología , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Infecciones por Virus de Epstein-Barr/tratamiento farmacológico , Infecciones por Virus de Epstein-Barr/patología , Furanos/síntesis química , Herpesvirus Humano 4/fisiología , Humanos , Interacciones Hidrofóbicas e Hidrofílicas , Toxinas de Lyngbya/farmacología , Metilación , Neoplasias/tratamiento farmacológico , Neoplasias/patología , Ésteres del Forbol/efectos adversos , Ésteres del Forbol/farmacología , Unión Proteica , Proteína Quinasa C-delta/antagonistas & inhibidores , Proteína Quinasa C-delta/metabolismo , Compuestos de Espiro/síntesis química , Relación Estructura-Actividad
16.
Indian J Exp Biol ; 49(11): 857-63, 2011 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-22126017

RESUMEN

In the present study, the putative potential of pericarp of dried fruit of Zanthoxylum (Rutaceae Family), a common spice additive in India's west coast cuisines, in protecting against carcinogenesis has been reported. Extract from dried fruit of Zanthoxylum was orally administered to mice at two dose levels: 100 and 200 mg/kg body wt. for 14 days. Results reveal bifunctional nature of Zanthoxylum species as deduced from its potential to induce phase-I and phase-II enzyme activities associated with carcinogen activation and detoxification in the liver of mice. Hepatic glutathione S-transferase and DT-diaphorase were found significantly elevated by the treatment. Zanthoxylum was also effective in augmenting the antioxidant enzyme activities of glutathione peroxidase, superoxide dismutase and catalase albeit significantly by high dose of the extract (P < 0.05; P < 0.01). Reduced glutathione was also significantly elevated in the liver of treated animals (P < 0.05). The present study also investigated peri-initiation application of acetone extract of Zanthoxylum on initiated mouse skin. Results showed a significant reduction in tumor incidence from 68% to 36% (P < 0.05); as well as, a reduction in tumor burden per effective mouse from 3.87 to 0.72 (P < 0.01). Cumulatively, the findings strongly suggest cancer chemopreventive potential of Zanthoxylum sps.


Asunto(s)
Carcinógenos/metabolismo , Glutatión Transferasa/metabolismo , NAD(P)H Deshidrogenasa (Quinona)/metabolismo , Papiloma/prevención & control , Zanthoxylum/química , Animales , Carcinógenos/antagonistas & inhibidores , Quimioprevención , Modelos Animales de Enfermedad , Frutas/química , Glutatión/metabolismo , Hígado/patología , Masculino , Ratones , Papiloma/patología , Extractos Vegetales/química , Extractos Vegetales/metabolismo , Extractos Vegetales/farmacología , Neoplasias Cutáneas/patología
17.
Anticancer Agents Med Chem ; 21(16): 2100-2110, 2021 10 28.
Artículo en Inglés | MEDLINE | ID: mdl-33573577

RESUMEN

BACKGROUND: Sanguinarine, a kind of benzophenanthridine alkaloid, is a natural compound with potential development value for its anticancer activity. Hundreds of studies have been carried out in vivo or in vitro, trying to make it feasible for the anticancer clinic medication of sanguinarine. However, sanguinarine was branded as a toxicant or even a carcinogen according to some toxicological experiments and cancer investigations. OBJECTIVE: Aiming at safety and effectiveness of sanguinarine, this article reviews the extant information on present studies of sanguinarine, and both anticancer carcinogenesis mechanism details are summarized. The future potential research directions of this valued compound are also discussed to provide reference for future drugs development. METHODS: PubMed, Web of Science, CNKI and WanFang databases were used to search current studies and experimental researches about anticancer effect or carcinogenic information of sanguinarine. RESULTS: Our results indicated that sanguinarine exhibited anticancer effect through anti-proliferation, anti-invasion, anti-angiogenesis and apoptosis within cancer lesion. Also, many clinical investigations indicated that sanguinarine and its related products might be associated to pre-carcinoma within oral or skin potentially. CONCLUSION: Sanguinarine is a natural compound with good development value for its potent anticancer activity; however, its carcinogenesis effect should also be taken seriously. Studies on structural modification and analogue design should be carried out to improve its safety and efficiency in the future.


Asunto(s)
Antineoplásicos/farmacología , Benzofenantridinas/farmacología , Carcinógenos/antagonistas & inhibidores , Isoquinolinas/farmacología , Neoplasias/tratamiento farmacológico , Antineoplásicos/química , Benzofenantridinas/química , Proliferación Celular/efectos de los fármacos , Humanos , Isoquinolinas/química , Neoplasias/patología
18.
Comput Math Methods Med ; 2021: 4883509, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34956398

RESUMEN

Accumulating studies revealed association between development of glioma and miRNA dysregulation. A case in point is miR-381-3p, but its mechanism in glioma is unclear yet. In this work, we confirmed that overexpressed miR-381-3p repressed biological functions of glioma cells. Additionally, we also discovered that upregulated anthrax toxin receptor 1 (ANTXR1) was negatively mediated by miR-381-3p. We further proved that miR-381-3p-targeted ANTXR1 was able to counteract the suppression of miR-381-3p on biological functions of glioma. We concluded that miR-381-3p and ANTXR1 were both important factors in modulating glioma progression. miR-381-3p/ANTXR1 axis is expected to be a molecular target for glioma.


Asunto(s)
Neoplasias Encefálicas/genética , Glioma/genética , MicroARNs/genética , Proteínas de Microfilamentos/antagonistas & inhibidores , Receptores de Superficie Celular/antagonistas & inhibidores , Carcinógenos/antagonistas & inhibidores , Línea Celular Tumoral , Biología Computacional , Progresión de la Enfermedad , Regulación hacia Abajo , Regulación Neoplásica de la Expresión Génica , Humanos , Proteínas de Microfilamentos/genética , Receptores de Superficie Celular/genética , Regulación hacia Arriba
19.
Food Chem Toxicol ; 157: 112582, 2021 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-34582963

RESUMEN

The present study investigated the protective effects and mechanism of action of cyanidin-3-O-glucoside (C3G) and its major metabolite protocatechuic acid (PCA) against 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) induced cytotoxicity in HepG2 cells. The results demonstrated that C3G and PCA dose-dependently suppressed PhIP-induced mutation in Salmonella typhimurium TA98, and inhibited PhIP-induced cytotoxicity and apoptosis in HepG2 cells. Western blot analysis indicated that C3G and PCA minimized PhIP-induced cell damage by reversing the abnormal expression of Bax/Bcl-2, Cytochrome c, cleaved Caspase-3, XIAP, Nrf2, HO-1, LC3 and p62 involved in intrinsic apoptotic and Nrf2/p62 pathways. Molecular docking results revealed that C3G and PCA were able to interfere with Nrf2 signaling and apoptotic cascade through binding to Keap1 and Bcl-2. Moreover, the protective effect of C3G was stronger than that of PCA. These findings suggested that dietary consumption of food sources rich in C3G can fight against the health risks of heterocyclic aromatic amines.


Asunto(s)
Antocianinas/farmacología , Apoptosis/efectos de los fármacos , Carcinógenos/toxicidad , Glicósidos/farmacología , Células Hep G2/efectos de los fármacos , Hidroxibenzoatos/farmacología , Imidazoles/toxicidad , Factor 2 Relacionado con NF-E2/metabolismo , Proteínas de Unión al ARN/metabolismo , Transducción de Señal/efectos de los fármacos , Carcinógenos/antagonistas & inhibidores , Células Hep G2/metabolismo , Humanos , Imidazoles/antagonistas & inhibidores , Simulación del Acoplamiento Molecular
20.
Curr Cancer Drug Targets ; 21(1): 21-54, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33023449

RESUMEN

CYP1A1 and CYP1B1 are extrahepatic P450 family members involved in the metabolism of procarcinogens, such as PAHs, heterocyclic amines and halogen-containing organic compounds. CYP1A1/1B1 also participate in the metabolism of endogenous 17-ß-estradiol, producing estradiol hydroquinones, which are the intermediates of carcinogenic semiquinones and quinones. CYP1A1 and CYP1B1 proteins share approximately half amino acid sequence identity but differ in crystal structures. As a result, CYP1A1 and CYP1B1 have different substrate specificity to chemical procarcinogens. This review will introduce the general molecular biology knowledge of CYP1A1/1B1 and the metabolic processes of procarcinogens regulated by these two enzymes. Over the last four decades, a variety of natural products and synthetic compounds which interact with CYP1A1/1B1 have been identified as effective chemo-preventive agents against chemical carcinogenesis. These compounds are mainly classified as indirect or direct CYP1A1/1B1 inhibitors based on their distinct mechanisms. Indirect CYP1A1/1B1 inhibitors generally impede the transcription and translation of CYP1A1/1B1 genes or interfere with the translocation of aryl hydrocarbon receptor (AHR) from the cytosolic domain to the nucleus. On the other hand, direct inhibitors inhibit the catalytic activities of CYP1A1/1B1. Based on the structural features, the indirect inhibitors can be categorized into the following groups: flavonoids, alkaloids and synthetic aromatics, whereas the direct inhibitors can be categorized into flavonoids, coumarins, stilbenes, sulfur containing isothiocyanates and synthetic aromatics. This review will summarize the in vitro and in vivo activities of these chemo-preventive agents, their working mechanisms, and related SARs. This will provide a better understanding of the molecular mechanism of CYP1 mediated carcinogenesis and will also give great implications for the discovery of novel chemo-preventive agents in the near future.


Asunto(s)
Carcinogénesis , Carcinógenos , Citocromo P-450 CYP1A1 , Citocromo P-450 CYP1B1 , Inhibidores Enzimáticos del Citocromo P-450/farmacología , Antineoplásicos/farmacología , Carcinogénesis/inducido químicamente , Carcinogénesis/efectos de los fármacos , Carcinógenos/antagonistas & inhibidores , Carcinógenos/química , Carcinógenos/metabolismo , Quimioprevención/métodos , Citocromo P-450 CYP1A1/genética , Citocromo P-450 CYP1A1/metabolismo , Citocromo P-450 CYP1B1/genética , Citocromo P-450 CYP1B1/metabolismo , Humanos , Fenómenos Químicos Orgánicos , Relación Estructura-Actividad
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda